Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Each year in the UK, over 300 patients are diagnosed with myelofibrosis,  a blood cancer associated with debilitating symptoms including extreme fatigue, pain, weakness and shortness of breath. Around 10-20% of patients go on to develop acute myeloid leukaemia, with median survival from the time of diagnosis just 2 years for patients with high-risk disease.

Stem cell transplant are the only cure for myelofibrosis, but this is only suitable for a small minority of younger patients who don't have other conditions as well. Instead, the standard NHS care for the illness is treatment with a drug called ruxolitnib, but many patients do not respond to this treatment.

Professor Mead said "The PROMise study is a really exciting study that has just opened in the UK and will be opening across 15 centres. This is introducing a new treatment called PLX2853, in combination with ruxolitininb, for patients with MF (myelofibrosis)."

Read the full story on the Radcliffe Department of Medicine website.

Similar stories

Lister Research Prize Fellows Announced

James Davies has been named as one of eight researchers selected for the 2022 Fellowship scheme.

New Associate Professor titles conferred

Stephen Twigg and Adam Wilkinson have both been awarded Associate Professor titles in the most recent announcement from the Radcliffe Department of Medicine

Research shines at the MRC WIMM Post-doc Symposium

Held on 16th June 2022 at Somerville College in Oxford, the one-day event brought together post-doctoral researchers from across the Institute to share their research.

MRC WIMM fundraising raises £583 for the British Red Cross

We are delighted to announced the result of fundraising efforts across the past few months.

MRC WIMM research at the 2022 Cheltenham Science Festival

'The Butterfly Effect: Covid-19 and Our Ancestors' ran on 8th June 2022 at the Parabola Arts Centre in Cheltenham.

Ita Askonas Medal Winner 2022

This year’s Student Presentation Day saw researchers from across the MRC WIMM gather to celebrate the work of students at the institute.